Carboxylesterase-2 is a highly sensitive target of the antiobesity agent orlistat with profound implications in the activation of anticancer prodrugs-Reference-Cited by-同舟云学术

Carboxylesterase-2 is a highly sensitive target of the antiobesity agent orlistat with profound implications in the activation of anticancer prodrugs

Published:2013-02 Issue:3 Volume:85 Page:439-447
ISSN:0006-2952
Container-title:Biochemical Pharmacology
language:en
Short-container-title:Biochemical Pharmacology

Author:

Xiao Da,Shi Deshi,Yang Dongfang,Barthel Benjamin,Koch Tad H.,Yan Bingfang

Publisher

Elsevier BV

Subject

Pharmacology,Biochemistry

Reference41 articles.

1. Insulin resistance, hyperglycemia, and atherosclerosis;Bornfeldt;Cell Metab,2011

2. Sleep and metabolic function;Morselli;Pflugers Arch,2012

3. Nutraceutical approach for preventing obesity-related colorectal and liver carcinogenesis;Shimizu;Int J Sci,2012

4. 10,000 treated in hospital for being dangerously fat as admissions rise TENFOLD in a decade 2011; http://www.dailymail.co.uk/health/article-1360210/Obesity-crisis-Hospitals-treat-10-000-patients-dangerously-fat.html#ixzz1p6Ux7QNJ.

5. Reinberg S. (2011) http://abcnews.go.com/Health/Healthday/story?id=8184975&-page=1#. T2CzwoEpZK0.

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identification of the first selective bioluminescent probe for real-time monitoring of carboxylesterase 2 in vitro and in vivo;The Analyst;2024

2. Carboxylesterase-activated near-infrared fluorescence probe for highly sensitive imaging of liver tumors;Journal of Materials Chemistry B;2024

3. Evaluation of Drug-Drug Interactions via Inhibition of Hydrolases by Orlistat, an Anti-Obesity Drug;Drug Metabolism and Disposition;2023-05-03

4. A hemicyanine-based fluorescent probe for simultaneous imaging of Carboxylesterases and Histone deacetylases in hepatocellular carcinoma;Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy;2022-11

5. Covalent CES2 Inhibitors Protect against Reduced Formation of Intestinal Organoids by the Anticancer Drug Irinotecan;Current Drug Metabolism;2022-10